Evidence map›Paper›PMID 35685451›Full record

ArticleARYA atherosclerosis2021

Serum interleukin-18 and its relationship with subclinical atherosclerosis in systemic lupus erythematosus.

Zahra Rezaieyazdi, Mina AkbariRad, Nayyereh Saadati, Masoumeh Salari, Reza Orang, Sima Sedighi, Habibollah Esmaily, Mahmoud Reza Azarpazhooh, Abdollah Firoozi, Ensieh Akbarpour

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ARYA atherosclerosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Photodynamic Therapy for Atherosclerosis.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Zahra RezaieyazdiRheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mina AkbariRadAssistant Professor, Department of Internal Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Nayyereh SaadatiRheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Masoumeh SalariRheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Reza OrangRheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Sima SedighiGolestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Habibollah EsmailyDepartment of Epidemiology and Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
Mahmoud Reza AzarpazhoohDepartment of Neurology, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Abdollah FirooziPharmacist, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Ensieh AkbarpourDepartment of Epidemiology and Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IRGhaem Hospital · IRGolestan University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterleukin-18 (IL-18) is a pro-inflammatory and pro-atherogenic factor, and its blood level has shown a direct correlation with atherosclerosis. We aimed to evaluate the serum IL-18 level in patients with systemic lupus erythematosus (SLE) and its relationship with the intima-media thickness (IMT) of the carotid artery in these patients, as an indicator of atherosclerosis.

methodsIn this cross-sectional study, 60 patients as the patient group and 30 healthy volunteers as the control group [matched sex, age, and body mass index (BMI)] were selected, and their disease status and general data were gathered using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) form. A blood sample was also obtained from all participants to determine the serum level of IL-18 and other metrics, including high-sensitivity C-reactive protein (hs-CRP), cholesterol, triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), anti-double stranded deoxyribonucleic acid (anti-dsDNA), complement 3 (C3), and C4. The IMT of the carotid artery was calculated in both groups. We also evaluated the clinical cardiovascular manifestations.

resultsThe serum IL-18 levels in patients were significantly higher than in the control group (P ˂ 0.005). It had no significant correlation with disease activity (P = 0.10). The patients with SLE with high IL-18 serum levels (> 280 pg/ml) had higher SLEDAI-2K (P = 0.02) than the patients with a low level (< 280), where 280 was the median of the IL-18 levels. The serum IL-18 level had no significant correlation with the carotid artery IMT.

conclusionA high level of IL-18 reflects the disease activity, but it was not significantly correlated with subclinical atherosclerosis, denoted by the carotid artery IMT.

Indexed as

AtherosclerosisInterleukin-18Systemic Lupus Erythematosus

Identifiers

PMID35685451
PMCPMC9145840
OpenAlexW4285745742

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.